Antitumor agent-145, identified by its CAS number 2983120-65-4, is a synthetic compound that has been studied for its potential therapeutic applications in oncology. While specific details about its chemical structure and mechanism of action may not be widely available, compounds in this category typically exhibit properties that inhibit tumor growth or induce apoptosis in cancer cells. Such agents often target specific molecular pathways involved in cell proliferation and survival, potentially leading to reduced tumor size or improved patient outcomes. The effectiveness and safety profile of antitumor agents like this one are usually evaluated through preclinical studies and clinical trials, assessing their pharmacokinetics, bioavailability, and toxicity. Additionally, the development of resistance in cancer cells is a critical consideration in the research of these agents. Overall, antitumor agent-145 represents a part of the ongoing efforts to discover and develop novel cancer therapies that can provide more effective treatment options for patients.

Antitumor agent-145

2983120-65-4: Antitumor agent-145, identified by its CAS number 2983120-65-4, is a synthetic compound that has been studied for its potential therapeutic applications in oncology. While specific details about its chemical structure and mechanism of action may not be widely available, compounds in this category typically exhibit properties that inhibit tumor growth or induce apoptosis in cancer cells. Such agents often target specific molecular pathways involved in cell proliferation and survival, potentially leading to reduced tumor size or improved patient outcomes. The effectiveness and safety profile of antitumor agents like this one are usually evaluated through preclinical studies and clinical trials, assessing their pharmacokinetics, bioavailability, and toxicity. Additionally, the development of resistance in cancer cells is a critical consideration in the research of these agents. Overall, antitumor agent-145 represents a part of the ongoing efforts to discover and develop novel cancer therapies that can provide more effective treatment options for patients.

<p>Compound Ir5 (Antitumor agent-145) serves as a tumor inhibitor characterized by significant fluorescence and mitochondrial targeting. It promotes anti-cancer activity by inducing necroptosis and stimulating the necroptosis-related immune response [1].</p>

CAS 2983120-65-4

Antitumor agent-145

Antitumor agent-145

Ref: TM-T85706